PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

PTC Therapeutics (NASDAQ: PTCT) approved an inducement equity award on Jan. 2, 2026 granting 300 restricted stock units (RSUs) to a new non-executive employee. Each RSU represents the right to one share of common stock upon vesting. The award was approved by the company's Compensation Committee and made under the Nasdaq inducement grant exception (Listing Rule 5635(c)(4)) as part of the employee's hire compensation. The RSUs vest over four years, with 25% vesting on each annual anniversary of the hire date, subject to continued service through each vesting date.

News Market Reaction

+0.88%

1 alert

+0.88% News Effect

On the day this news was published, PTCT gained 0.88%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Current share price: $76.85 RSU grant size: 300 RSUs Vesting duration: 4 years +5 more

8 metrics

Current share price $76.85 Pre-news market context

RSU grant size 300 RSUs Inducement grant to one new non-executive employee

Vesting duration 4 years RSUs vest over four years subject to continued service

Annual vesting rate 25% per year 25% of original RSUs vest on each annual anniversary

52-week high $87.50 Pre-news 52-week trading range

52-week low $35.95 Pre-news 52-week trading range

Market cap $6,201,468,678 Pre-news equity value

Volume vs average 1.33x Today’s volume vs 20-day average before this news

Market Reality Check

Price: $75.25 Vol: Volume 1,624,259 is 1.33x...

normal vol

$75.25 Last Close

Volume Volume 1,624,259 is 1.33x the 20-day average of 1,218,233 shares. normal

Technical Shares trade above the 200-day MA, at $76.85 vs 200-day MA of $57.82.

Peers on Argus

Pre-news, PTCT was up 0.7% with mixed peers: RNA and TGTX up modestly, while CRS...

Pre-news, PTCT was up 0.7% with mixed peers: RNA and TGTX up modestly, while CRSP, MRUS, and KRYS were down, indicating stock-specific rather than broad sector momentum.

Historical Context

5 past events · Latest: Dec 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 22	Drug approval Japan	Positive	+0.4%	MHLW approval of Sephience for PKU across all ages and severities.
Dec 19	Inducement grants	Neutral	+0.4%	Equity inducement grants to five new employees under Nasdaq Rule 5635(c)(4).
Dec 18	Conference presentation	Neutral	-0.5%	Announcement of J.P. Morgan Healthcare Conference presentation and webcast details.
Dec 01	Inducement grants	Neutral	-7.9%	Inducement equity grants for 15 new employees including options and RSUs.
Nov 20	R&D Day event	Positive	+1.1%	Planned R&D Day to highlight small molecule splicing and inflammation platforms.

Pattern Detected

Recent headlines show positive regulatory wins and routine corporate updates, with generally modest price moves except for one sharper decline following inducement grants.

Recent Company History

Over the last several months, PTC reported notable milestones and routine corporate items. On Dec. 22, 2025, Japanese MHLW approval of Sephience for PKU across all ages and severities coincided with a modest 0.42% gain. Multiple prior inducement grant announcements under Nasdaq Listing Rule 5635(c)(4) on Dec. 19 and Dec. 1, 2025 involved relatively small equity awards but one aligned with a sharp -7.9% move. Conference and R&D Day announcements around November and December produced limited, mixed reactions. Today’s small inducement RSU grant fits this pattern of recurring HR-related equity news.

Market Pulse Summary

This announcement details a small 300 RSU inducement grant to a new non-executive employee under Nas...

Analysis

This announcement details a small 300 RSU inducement grant to a new non-executive employee under Nasdaq Listing Rule 5635(c)(4), vesting over four years with 25% annually. It follows prior inducement grant disclosures in late 2025, suggesting a pattern of standardized hiring-related equity awards. In context of earlier regulatory wins and corporate events, this filing appears administrative. Investors often track the scale and frequency of such grants alongside broader earnings, pipeline, and insider trading disclosures.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4), inducement grant

4 terms

restricted stock units financial

"approved 300 restricted stock units ("RSUs"), each representing the right"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"300 restricted stock units ("RSUs"), each representing the right to receive"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"pursuant to the Nasdaq inducement grant exception ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement grant financial

"The inducement grant was approved by PTC's Compensation Committee"

An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.

AI-generated analysis. Not financial advice.

WARREN, N.J., Jan. 8, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 2, 2026, the company approved 300 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee. The award was made pursuant to the Nasdaq inducement grant exception as a component of the new hire's employment compensation.

The inducement grant was approved by PTC's Compensation Committee on Jan. 2, 2026, and is being made as an inducement material to the employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs each will vest over four years, with 25% of the original number of shares vesting on each annual anniversary of the employee's new hire date until fully vested, subject to the employee's continued service with the company through the vesting dates.

ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, Facebook, X, and Instagram.

For more information, please contact:

Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri@ptcbio.com

Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302656185.html

SOURCE PTC Therapeutics, Inc.

FAQ

What did PTC Therapeutics (PTCT) announce on Jan. 2, 2026 about equity awards?

PTC approved 300 RSUs for a new non-executive employee on Jan. 2, 2026, under the Nasdaq inducement grant exception.

How do the 300 RSUs granted by PTCT vest and when are shares delivered?

The RSUs vest over four years, with 25% vesting on each annual anniversary of the employee's hire date, subject to continued service.

Which Nasdaq rule did PTC use for the inducement grant for PTCT shares?

The award was made pursuant to Nasdaq Listing Rule 5635(c)(4), the inducement grant exception for new-hire compensation.

Who approved the inducement grant for PTC Therapeutics (PTCT)?

The company's Compensation Committee approved the inducement grant on Jan. 2, 2026.

Does the announcement state the RSUs convert to common stock automatically?

Each RSU represents the right to receive one share of common stock upon vesting, subject to the vesting schedule and continued service.